Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement C3 as a potential drug target in periodontitis: Evidence from the cis-Mendelian randomization approach.

Journal of clinical periodontology - 1 Feb 2024

Alayash Zoheir, Baumeister Sebastian-Edgar, Holtfreter Birte, Kocher Thomas, Baurecht Hansjörg, Ehmke Benjamin, Nolde Michael, Reckelkamm Stefan Lars

Abstract excerpt

AIM: Evidence from a Phase IIa trial showed that a complement C3-targeted drug reduced gingival inflammation in patients with gingivitis. Using drug-target Mendelian randomization (MR), we investigated whether genetically proxied C3 inhibition alters the risk of periodontitis. MATERIALS AND METHODS: We used multiple 'cis' instruments from the vicinity of the encoding loci of C3. Instrument selection was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement C3
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement system in diseases

Share to Genome-Wide Association Study

Share to Gingivitis

Share to Mendelian Randomization Analysis

Share to Periodontitis

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 37926509
DOI: 10.1111/jcpe.13894

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement C3 as a potential drug target in periodontitis: Evidence from the cis-Mendelian randomization approach.PMID 37926509Read ↗

Using human genetics to validate complement C3 as a drug target in periodontitisSemantic proximity Read ↗

Using genetics to explore complement C5 as a druggable protein in periodontitis.Semantic proximity Read ↗

Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis.Semantic proximity Read ↗

Genetically Supported Drug Targets and Dental Traits: A Mendelian Randomization Study.Semantic proximity Read ↗

Multi-Omics Integration Reveals the Genetic Mechanisms of Periodontitis and Predicts Therapeutic Drugs.Semantic proximity Read ↗

Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization studySemantic proximity Read ↗

Causal effect of chloride intracellular channel protein 5 on chronic periodontitis: A Mendelian randomization study.Semantic proximity Read ↗

Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes.Semantic proximity Read ↗

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention.Semantic proximity Read ↗

Fibroblast derived C3 promotes the progression of experimental periodontitis through macrophage M1 polarization and osteoclast differentiationSemantic proximity Read ↗

RSPO4 is a potential risk gene of stages III-IV, grade C periodontitis through effects on innate immune response and oral barrier integrity.Semantic proximity Read ↗

Cannabis use and the risk of periodontitis: A two-sample Mendelian randomization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.